The short version
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that roughly 14 of the 19 peptides the FDA had moved to Category 2 in September 2023 were going back to Category 1. That means compounding pharmacies can prepare them again, which reopens legal access for a set of peptides that had effectively vanished from US pharmacy shelves for about two and a half years.
This guide explains what the categories mean, which peptides came back, which did not, and what it changes for anyone who actually uses compounded peptides.
What Category 1 and Category 2 mean
The FDA keeps a "503A bulk drug substance" list that decides what compounding pharmacies can and cannot prepare. It has two relevant buckets:
- Category 1. The bulk substance is eligible for use in compounding. A pharmacy can prepare it against a prescription. It is not the same as FDA approval of a finished drug product, which is a much higher bar.
- Category 2. The FDA has identified a significant safety concern. A pharmacy cannot legally compound from the substance. In practice, Category 2 is a compounding ban.
When 17 peptides moved to Category 2 in September 2023, the FDA pointed at safety concerns and a lack of manufacturer-grade data. Compounding pharmacies stopped. Clinics that had been prescribing compounded peptides for off-label use either paused or pivoted to research-only channels.
The 2026 reclassification does not claim the 2023 decision was wrong. It says that for most of the peptides, the evidence now sits in Category 1.
Which peptides came back
Based on the February 2026 HHS announcement and the reporting around it, the peptides that appear to be back on Category 1 include:
| Peptide | Common research use |
|---|---|
| Ipamorelin | Selective ghrelin mimetic, pulsatile GH release |
| CJC-1295 (no DAC) | GHRH analog, often stacked with a GHRP |
| Sermorelin | GHRH 1-29 fragment, earlier GH axis research |
| Tesamorelin | GHRH analog, FDA-approved as Egrifta for HIV lipodystrophy |
| GHRP-2 | Older ghrelin receptor agonist |
| GHRP-6 | Older ghrelin receptor agonist |
| Hexarelin | Another older GHRP with higher potency |
| PT-141 (Bremelanotide) | Melanocortin receptor agonist, sexual arousal research |
| Thymosin Alpha-1 | Immune modulation, Hepatitis B adjunct work historically |
| Thymulin | Immune modulation |
| Epitalon | Pineal peptide, telomere biology |
| LL-37 | Antimicrobial peptide, wound healing research |
The FDA has not posted a single consolidated list, so pharmacies are working from HHS guidance and their own regulatory review. If the peptide you care about is not on this table, assume it is still worth calling a compounding pharmacy and asking directly. The reporting across several outlets has minor inconsistencies at the edges.
For calculators on the peptides you can now get through compounding channels, we have:
- Ipamorelin peptide calculator
- CJC-1295 and Ipamorelin stack calculator
- Sermorelin peptide calculator
- PT-141 peptide calculator
- Semax peptide calculator (was always Category 1 but pairs naturally with this list)
Which peptides stayed restricted
The announcement named Melanotan II as a peptide that stayed on Category 2. The signal there is a mix of cardiovascular concerns at higher doses and the dermatology community flagging melanoma risk from unregulated tanning use. A handful of other peptides remained under review in the transition period. The coverage does not converge on a single list for these, which is why guidance from a specific compounding pharmacy beats guidance from a summary article.
What actually changes
Three practical things change with the reclassification.
Compounding pharmacies can resume. The ones that paused in 2023 and held onto their bulk drug substance documentation can go back into production for the reclassified peptides. That means legal prescriptions, third-party lab testing, and traceability from a US pharmacy rather than a grey-market source overseas.
Prices should drift down as supply returns. Scarcity drove up peptide prices after the 2023 decision. As more pharmacies come online, wholesale pricing on the reclassified peptides should ease. Retail prices follow on a lag.
Clinicians get an off-label path again. Off-label prescribing was never banned, but compounded access is what made a lot of practical use possible. For things like sermorelin-based growth hormone axis support or ipamorelin in a recovery protocol, a prescription and a compounding pharmacy together make the rest of it work.
What does not change is the underlying evidence. A Category 1 peptide is a legal-to-compound peptide, not a proven-effective drug. The randomized controlled trial base for most of these peptides is thin or absent. The 2026 reclassification reopens the door. It does not redo the clinical work that was never done.
What to ask a compounding pharmacy now
If you are talking to a compounding pharmacy about any of the peptides on the reclassified list, the questions that matter are the same ones you would ask about any compounded product:
- Where do you source the bulk peptide, and is it a registered 503A supplier?
- Will you share the certificate of analysis on the batch I am prescribed?
- What purity do you test to? (HPLC above 98% is the normal target.)
- What is the reconstituted shelf life you guarantee?
The regulatory change makes the rest of these questions easier to ask, because the pharmacy now has a legal answer for the top of the stack. The quality questions were always the real work.
What about retatrutide, CagriSema, and the GLP-1 next generation?
None of the next-generation weight loss peptides are part of this story. Retatrutide is Lilly's investigational triple agonist, and its NDA filing is expected in Q4 2026. CagriSema is Novo Nordisk's cagrilintide plus semaglutide combination, with an FDA decision expected in late 2026. Those are moving through the standard drug approval pathway, not the compounding pathway. The 503A reclassification is a separate system.
If you want calculators for the current GLP-1 generation, we have:
- Retatrutide reconstitution calculator
- Tirzepatide reconstitution calculator
- Semaglutide reconstitution calculator
Sources and further reading
The announcement and its interpretation pulled from several outlets, not a single FDA document. ProPublica has covered the safety debate around reopening compounded peptide access. Oath Research and the Peptide Database both published deeper breakdowns of the category changes. Reporting dates run from late February through March 2026.
Bottom line: about 14 peptides are back on the legal-to-compound list in the US. A few, including Melanotan II, are not. Compounding pharmacies are the fastest way to find out whether the one you care about is available right now.